Research location

Xi'an

Shaanxi, China

Published trials367

Site observations471

Linked trials published367

Page1 / 8

Research activity in Xi'an

Shaanxi, China

CureCurrent currently publishes aggregate city-level research activity for this location: 367 trials and 471 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Xi'an

367 linked trials · page 1 of 8

Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPSNCT07799948 · 2026-09-01 · 1 site observation

Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUreNCT07687186 · 2026-06-22 · 2 site observations

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22 · 1 site observation

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation

Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple SclerosisNCT07587125 · 2026-05-08 · 1 site observation

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)NCT07416474 · 2026-04-03 · 1 site observation

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16 · 2 site observations

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation

Plasma Exosomal RNA Signature for Prostate Cancer Bone MetastasisNCT07553754 · 2026-03-12 · 3 site observations

Phase II Trial of RC1416 Injection in AsthmaNCT07403487 · 2026-03-10 · 1 site observation

A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate CancerNCT07474142 · 2026-03-03 · 3 site observations

A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionNCT07367529 · 2026-02-26 · 1 site observation

Study on the Cosmetic Outcome and Safety Evaluation of 3D Printed Biodegradable Biological Mesh for One-Stage Breast Reconstruction After Radical MastectomyNCT07365267 · 2026-01-15 · 1 site observation

Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation on Alleviating Major Depressive Disorder in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention:A Prospective, Double-Blind,Randomized Controlled StudyNCT07454070 · 2026-01-06 · 1 site observation

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02 · 1 site observation

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)NCT07262645 · 2025-12-10 · 3 site observations

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBCNCT07178171 · 2025-11-06 · 1 site observation

A Study of Ivonescimab in First-Line ES-SCLCNCT07245446 · 2025-10-29 · 1 site observation

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28 · 1 site observation

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerNCT07043725 · 2025-09-15 · 3 site observations

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)NCT07154706 · 2025-08-21 · 1 site observation

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerNCT07047365 · 2025-07-25 · 2 site observations

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 2 site observations

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · 2025-07-23 · 1 site observation

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)NCT07060807 · 2025-07-21 · 1 site observation

A Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With SurgeryNCT07071402 · 2025-07-18 · 1 site observation

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid TumorsNCT06953089 · 2025-07-18 · 1 site observation

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 2 site observations

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerNCT07003074 · 2025-06-23 · 1 site observation

Effect of a Pharmacist-led Multifaceted Intervention on Treatment Outcomes in Hypertensive PatientsNCT06558877 · 2025-06-20 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)NCT06991257 · 2025-06-19 · 1 site observation

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerNCT06891833 · 2025-06-05 · 2 site observations

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaNCT06977581 · 2025-05-20 · 1 site observation

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerNCT06892548 · 2025-05-02 · 1 site observation

3D-printed Biodegradable Breast Implants for Breast RestorationNCT06993714 · 2025-05-01 · 1 site observation

TQC2731 Clinical Trial for the Treatment of Severe Asthma With InjectionNCT06829784 · 2025-03-21 · 5 site observations

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16 · 1 site observation

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25 · 1 site observation

Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled TrialNCT06938360 · 2025-02-20 · 1 site observation

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCNCT06864624 · 2025-02-18 · 1 site observation

Chronic Airway Disease and Multimorbidity CohortNCT06798077 · 2025-02-01 · 1 site observation

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06568939 · 2025-01-20 · 1 site observation

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerNCT07673029 · 2025-01-10 · 2 site observations

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.